Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 213

recruiting
3 977
countries
28
conditions
2 105

3 664 trials match your criteria

Ovarian cancer

Not recruiting

Study of olaparib, durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide

Post-acute COVID-19 syndrome

Not recruiting

Study of vericiguat to improve physical function in patients with Post-COVID-19 syndrome with or without chronic fatigue syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Vericiguat

Short-bowel syndrome

Not recruiting

Study on the Long-Term Safety and Effectiveness of Glepaglutide for Patients with Short Bowel Syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide

Cold urticaria

Not recruiting

Study on the Effectiveness and Safety of Barzolvolimab for Patients with Chronic Inducible Urticaria

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab

Circadian rhythm sleep disorder

Not recruiting

Study on the Effects of Tasimelteon for Patients with Delayed Sleep-Wake Phase Disorder

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tasimelteon

Myelofibrosis+1

Not recruiting

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Danazol

Spinal cord injury cervical

Not recruiting

Study on the Safety of NG004 for Patients with Acute Spinal Cord Injury

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:NG004

Metastatic malignant melanoma

Not recruiting

Study on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine

Mucopolysaccharidosis II

Not recruiting

Study on the Effectiveness and Safety of DNL310 vs Idursulfase for Children and Young Adults with Mucopolysaccharidosis Type II

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Idursulfase

Squamous cell carcinoma of skin+1

Not recruiting

Study of L19IL2 and L19TNF for Patients with Advanced Basal Cell Carcinoma or Cutaneous Squamous Cell Carcinoma Not Eligible for Surgery or Radiation

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bifikafusp Alfa

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of AZD5004 and Semaglutide for Adults with Type 2 Diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004

Hereditary angioedema with C1 esterase inhibitor deficiency+1

Not recruiting

Study on the Long-Term Safety of STAR-0215 for Adults with Hereditary Angioedema

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Navenibart

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.